Selinexor, Bortezomib, and Dexamethasone Combination Proves Effective for Myeloma
In December 2020, the FDA approved selinexor in combination with the proteasome inhibitor bortezomib and dexamethasone for patients with MM who have received at least 1 prior therapy.